What is PSTV's P/E ratio?

PLUS THERAPEUTICS INC (PSTV) currently trades at a P/E ratio of 4.88.

PLUS THERAPEUTICS INC reports a Return on Equity (ROE) of -99.75%.

What is PSTV's dividend yield?

PLUS THERAPEUTICS INC offers a dividend yield of 0.00%.

What is PSTV's Quality Score?

Our AI rates PSTV's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PSTV?

Our AI Timing Score for PSTV is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PSTV belong to?

PLUS THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

PSTV (NASDAQ) Stock Analysis | PLUS THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

PSTV AI Analysis Summary

Our AI summary for PSTV: PLUS THERAPEUTICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 4.88, ROE of -99.75%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PSTV

PLUS THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 88

USD 3.87

0.22 (6.03%) Day Change

Watchlist Portfolio Compare Chart

4.88

P/E

0.06

D/E

-99.8%

ROE

-59.9%

ROA

0.00%

Div Yield

-0.06

PEG

PLUS THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.87 Price 0.22 (6.03%) Day Change	NEWS SCORE: 88

PSTV, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	88
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.87
PBV / Sector	2.10 / 5.20
Earning Per Share	-1.84

PE / Sector	4.88 / 19.97 GREAT
PEG or PE/Growth / Sector	-0.06 / 1.22
Average 1M Daily Value	0.46 M GREAT
Average 1W Daily Value	0.26 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-230.24 / 98.71
NPM Average (%) / Sector	-2,040.98 / -1,721.76
NPM Change Average (%) / Sector	-17.12 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-59.91 / 27.02
ROA Average (%) / Sector	-118.91 / -368.17
ROA Change Average (%) / Sector	4.69 / 5,404.12
ROE (%) / Sector	-99.75 / 3.47
ROE Average (%) / Sector	31.66 / 6.51 GREAT
ROE Change Average (%) / Sector	-266.95 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:21
Symbol	PSTV
Name	PLUS THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	6.88 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	25.13 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 6420 LEVIT GREEN BOULEVARD, Houston, TX, United States, 77021

Phone: 737 255 7194

Website: https://plustherapeutics.com

Sector: Healthcare >> Biotechnology

Description: Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.